FAQ

WYE 125132

Known as: WYE-125132, WYE125132 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2012
01220102012

Related topics

Related topics

3 relations

Broader (2)

Phenylurea CompoundsPyrazoles

Narrower (1)

WYE-132

Related mentions per year

Related mentions per year

1950-2018
1960198020002020
WYE 125132
Pyrazoles
Phenylurea Compounds
WYE-132

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.
The mammalian target of rapamycin (mTOR) is the catalytic subunit of two multiprotein complexes, mTOR complex-1 (mTORC1) and mTOR… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
The mammalian target of rapamycin (mTOR) is a major component of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway that… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.
The mammalian target of rapamycin (mTOR) regulates growth via promoting translation and transcription. Here, employing an mTOR… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?